vsLAQUINIMOD

A clinical trial update

Phase 2

HUNTINGTONS

In the red corner,the undefeatedHUNTINGTONS

In the blue corner,the new-hopeful

LAQUINIMOD

How will itfight HD?

Laquinomid canchange the activity of

our immune system.

Normally, this helps us fight diseases by

stimulating inflammation.

But, in neurodegenerative diseases too much inflammation might

be a problem...

By slowing down the immune system

laquinomid could slow the progress of Huntingtons.

How do we know this?

By studying another diseasecalled Relapse-Remitting

Multiple Sclerosis...

A disease which getsworse, then betterthen even worseas it advances.

When it gets worse: too much inflammation

is the problem.

Laquinimod is being tested against this disease in

another trial calledConcerto...

Which is already in stage 3.

This experience fighting MSis good preparation for

its fight against Huntingtons.

It gives us crucial information about how it will behave in the ring - our bodies!

(There’s no point supporting laquinimod if it’s going

to do us harm)

What information have we learned about

Laquinimod?

We have learned:How much our bodies

can handle - a safe dose.

Also:What problems our bodies

could have - the side-effects.

This information means the HD-trial has started

in a strong position.

Legato-HD is now on phase 2.

Whats the aim of Phase 2?

To continue checking safety- to see what can we

consume on a daily basis.

To start testing efficacy- to see if it has an

effect on Huntingtons.

How will we know if it has?

By measuring Motor-score: a sign of how well a patient can control their movement.

If this score declines less in patients taking the drug,

Laquinimod is helping!

This is the studies primary end-point:

the trial will only continue if this improves after 12 months.

So, whats the story so far?

By June 2016400 adults - with

and without HD - were meant to be recruited.

They were to receivea daily dose of either:

a placebo, 0.5 mg, 1.0 mg, 1.5 mg.

In Jan 2016,it was decided to stop the 1.5 mg daily dose.

This was because of a recomendation from the

MS study, Concerto...

Some of their patients ona similar 1.2mg dose had heart problems.

As a result, no one new is being recruited to

to take the highest dose.

But, the other 2 doses and placebo are

still running.

The bad news:The recruitment deadline has been pushed back

(delaying the study)

The good news:They will now only need to

recruit 300 patients (one dose is missing)

Conclusion?

In a heavy-weight fight,information like this is

exactly what we need if...

We want to improve the odds of a win for

Laquinimod!

A visualscience presentation made by @DeLaSouz

for HDYO